Ligand Pharma(DE:LGDN)
€280.00+6.00 (+2.19%)
DE:LGDN
Ligand Pharma stock drug pipeline
€280.00
At close:+6.00 (+2.19%)
Ligand Pharma (LGDN) Drug Pipeline
1 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Sparsentan, Filspari, Re-021 | Immunoglobulin A Nephropathy | Phase II | Completed | A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN | May 03, 2023 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Sparsentan, Filspari, Re-021 | Phase II | Immunoglobulin A Nephropathy | Completed | A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN | May 03, 2023 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Ligand Pharmaceuticals Inc (DE:LGDN) have in its pipeline
Ligand Pharma DE:LGDN is currently developing the following drugs: Sparsentan, Filspari, Re-021. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
